$9.46
0.94% day before yesterday
Nasdaq, Oct 03, 10:10 pm CET
ISIN
US6700021040
Symbol
NVAX

Novavax, Inc. Stock price

$9.46
+2.06 27.84% 1M
+3.86 68.93% 6M
+1.42 17.66% YTD
-4.96 34.40% 1Y
-9.14 49.14% 3Y
-100.71 91.41% 5Y
-132.34 93.33% 10Y
-25.74 73.13% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
-0.09 0.94%
ISIN
US6700021040
Symbol
NVAX
Industry

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.2b
Net debt
positive
Cash
$612.3m
Shares outstanding
162.2m
Valuation (TTM | estimate)
P/E
4.0 | 3.9
P/S
1.4 | 1.4
EV/Sales
1.1 | 1.1
EV/FCF
negative
P/B
40.8
Financial Health
Equity Ratio
-40.0%
Return on Equity
30.1%
ROCE
38.7%
ROIC
84.0%
Debt/Equity
6.1
Financials (TTM | estimate)
Revenue
$1.1b | $1.1b
EBITDA
$407.5m | $466.5m
EBIT
$366.4m | $483.8m
Net Income
$422.8m | $390.9m
Free Cash Flow
$-635.7m
Growth (TTM | estimate)
Revenue
9.2% | 60.8%
EBITDA
269.2% | 354.3%
EBIT
228.0% | 308.6%
Net Income
243.6% | 308.5%
Free Cash Flow
-2,727.9%
Margin (TTM | estimate)
Gross
88.3%
EBITDA
37.8% | 42.5%
EBIT
34.0%
Net
39.2% | 35.6%
Free Cash Flow
-58.9%
More
EPS
$2.4
FCF per Share
$-3.9
Short interest
27.6%
Employees
952
Rev per Employee
$720.0k
Show more

Is Novavax, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Novavax, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Novavax, Inc. forecast:

9x Buy
64%
2x Hold
14%
3x Sell
21%

Analyst Opinions

14 Analysts have issued a Novavax, Inc. forecast:

Buy
64%
Hold
14%
Sell
21%

Financial data from Novavax, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,079 1,079
9% 9%
100%
- Direct Costs 126 126
65% 65%
12%
952 952
51% 51%
88%
- Selling and Administrative Expenses 228 228
49% 49%
21%
- Research and Development Expense 358 358
24% 24%
33%
408 408
269% 269%
38%
- Depreciation and Amortization 41 41
9% 9%
4%
EBIT (Operating Income) EBIT 366 366
228% 228%
34%
Net Profit 423 423
244% 244%
39%

In millions USD.

Don't miss a Thing! We will send you all news about Novavax, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novavax, Inc. Stock News

Neutral
PRNewsWire
5 days ago
GAITHERSBURG, Md. , Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding Novavax's Matrix-M® adjuvant.
Neutral
Investors Business Daily
17 days ago
The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters from Pfizer, Moderna and Novavax.
Neutral
Seeking Alpha
about one month ago
Novavax, Inc. (NASDAQ:NVAX ) Cantor Global Healthcare Conference 2025 September 4, 2025 10:20 AM EDT Company Participants John Jacobs - President, CEO & Director Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kelly - Executive VP, CFO & Treasurer Conference Call Participants Pete Stavropoulos - Cantor Presentation Pete Stavropoulos Welcome to the Cantor Global Hea...
More Novavax, Inc. News

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Head office United States
CEO John Jacobs
Employees 952
Founded 1987
Website www.novavax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today